Executive Summary
Overnight filings reveal a market bifurcated between robust operational performance and cautious insider behavior. While 15+ companies reported strong YoY revenue growth (e.g., WESCO +13%, Virtu Financial +19%, Yum China +13%), a significant wave of insider selling—particularly at Natera (6 executives), CoreWeave, and Roivant Sciences—signals potential valuation concerns or profit-taking at elevated levels.
The most material corporate action is the $8.5B Arcosa acquisition by CRH, reinforcing a consolidation trend in building materials. Mixed sentiment dominates, with many companies showing top-line strength but margin compression (e.g., Solstice Advanced Materials, Magnum Ice Cream) or declining cash flows (CRH, WESCO). The IPO pipeline is active with Braveheart Bio filing for a $319M offering. Key themes include data center/AI infrastructure demand (WESCO, AITX), margin discipline challenges, and a divergence between reported earnings and underlying cash generation.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Form 4 · Schedule 13D · S-1 · 10-Q · 8-K · 13F
Tracking the trend? Catch up on the prior US Pre-Market SEC Filings Roundup digest from July 23, 2026.
Investment Signals (12)
- CRH ↓ (BULLISH)▲
Q2 net income +13% YoY to $1.5B, Adjusted EBITDA margin +30 bps to 24.4%, and a transformative $8.5B Arcosa acquisition to bolster North American aggregates. Strong pricing and M&A execution
- WESCO International ↓ (BULLISH)▲
Record Q2 net sales of $6.7B (+13% YoY), data center sales surging +45% to $1.5B, and record backlog +60% YoY. Adjusted diluted EPS +35% to a record $4.57. Benefiting from secular AI infrastructure buildout
- Yum China ↓ (BULLISH)▲
Q2 revenue +13% YoY to $3.1B, 9th consecutive quarter of operating profit margin expansion, and record net new store openings of 560 (+67% YoY). Strong execution in a challenging consumer environment
- Schwab (Charles Schwab)▲
Co-Chairman Bettinger sold $20M of stock at ~$104, exercising options at $52 for a ~$10M profit. While a large sale, it follows a typical exercise-and-sell pattern. The stock's performance and insider's remaining 529K shares warrant monitoring [NEUTRAL/BEARISH]
- Roivant Sciences ↓ (BEARISH)▲
President & Immunovant CEO Venker sold $7M of stock at $34.95, exercising options at $3.85 for a massive gain. The sale was under a 10b5-1 plan, but the magnitude and profit-taking signal potential top-of-cycle thinking for the biotech
- Natera ↓ (BEARISH)▲
Six top executives (CEO, CFO, Chairman, President, CLO, President of Clinical Diagnostics) sold stock in a coordinated manner under 10b5-1 plans. Total sales exceeded $2.5M. While pre-planned, the breadth of selling across the C-suite is a significant negative signal
- CoreWeave ↓ (BEARISH)▲
Chief Development Officer McBee sold ~$4.85M in stock across multiple transactions, reducing his holdings to near zero (912 shares remaining). This near-total exit by a key executive is a major red flag for the AI cloud company
- Virtu Financial ↓ (NEUTRAL)▲
Q2 total revenues +19% YoY to $1.19B, but GAAP net income declined to $284.9M from $293M. Execution Services revenue fell 19.1% YoY, showing a mixed performance with core market-making strength offset by weakness in other segments
- Solstice Advanced Materials ↓ (BULLISH)▲
Q2 net sales +11% YoY, driven by Nuclear (+27%) and Electronic Materials (+15%), and raised full-year guidance. However, Adjusted EBITDA margin contracted 218 bps to 25.3% due to plant turnarounds. The announced Element Solutions acquisition is a major catalyst for H1 2027
- Willis Towers Watson ↓ (BULLISH)▲
Q2 revenue +9% YoY (organic +5%), adjusted diluted EPS +17% to $3.35, and adjusted operating margin +100 bps to 19.5%. Announced 'Propel' AI plan targeting ~30% margin by 2028 and increased buyback by $1.5B. Strong operational improvement and shareholder return
- Ambev ↓ (NEUTRAL)▲
Q2 consolidated net revenue +6.1% YoY, with Brazil beer volume +5.0% and normalized EBITDA +12.8%. However, CAC and LAS segments saw volume declines, and Canada EBITDA fell 2.9%. Strong domestic performance offset by international weakness
- BioCardia ↓ (BULLISH)▲
President and CEO Altman bought 5,000 shares at $0.78 (~$3.9K). While a small absolute amount, insider buying at a micro-cap biotech trading near cash value is a positive signal of management conviction
Risk Flags (10)
- Natera / Insider Selling↓ [HIGH RISK]▼
Six top executives, including the CEO and Chairman, sold shares in a coordinated manner under 10b5-1 plans. While pre-planned, the breadth and timing of sales across the entire C-suite is a significant risk indicator, suggesting potential concerns about valuation or future growth
- CoreWeave / Insider Exit↓ [HIGH RISK]▼
Chief Development Officer McBee sold nearly his entire stake (~$4.85M), leaving only 912 shares. A near-total exit by a key executive in a high-growth, capital-intensive AI company is a major red flag for corporate governance and management confidence
- CRH / Cash Flow Decline↓ [MEDIUM RISK]▼
Operating cash flow fell 28.7% to $513M in H1 2026, driven by a $1.8B increase in accounts receivable. Despite strong earnings, the company is consuming cash to fund growth, which could pressure liquidity if the trend continues
- WESCO / Cash Flow & Debt↓ [MEDIUM RISK]▼
Operating cash flow declined 50% YoY to $54M and free cash flow fell 63% to $32M, due to working capital needs. SG&A expenses rose 17.3% YoY, and interest expense increased due to higher debt. Rapid growth is consuming cash and pressuring margins
- Lincoln National / Annuity Outflows↓ [MEDIUM RISK]▼
Annuities net outflows worsened to $2.9B from $1.2B YoY, indicating persistent pressure in a key product line. Group Protection operating income also declined 15% YoY, showing weakness beyond the core Life Insurance business
- Magnum Ice Cream / Margin Compression↓ [MEDIUM RISK]▼
Overall adjusted EBITDA margin contracted 30 bps to 18.7%, with AMEA segment margin falling sharply from 26.2% to 23.5%. The company is facing cost inflation and competitive pricing pressure, particularly in emerging markets
- Solstice Advanced Materials / Margin Decline↓ [MEDIUM RISK]▼
Adjusted EBITDA margin contracted 218 bps to 25.3% despite strong revenue growth, due to plant turnaround activity. Corporate expenses also increased to $54M from $46M as a standalone public company, indicating cost headwinds
- NanoViricides / Dilutive Offering↓ [HIGH RISK]▼
The company announced a ~$3.8M registered direct offering, issuing shares and warrants. As a pre-revenue clinical-stage biotech, this offering dilutes existing shareholders and signals ongoing cash burn with no near-term revenue catalyst
- Braveheart Bio / IPO Risks↓ [HIGH RISK]▼
The company is filing for an IPO but is pre-revenue, relies on a single product candidate (BHB-1893) in-licensed from Hengrui, and all clinical trials to date were conducted by the licensor. Investors face significant binary risk and lack of control over clinical data
- Schwab / Insider Profit-Taking↓ [LOW RISK]▼
Co-Chairman Bettinger's $20M stock sale, while an exercise-and-sell pattern, is a large transaction. The stock's performance and the insider's remaining holdings should be monitored for further selling, which could signal a peak in the brokerage cycle
Opportunities (10)
- CRH / Arcosa Acquisition↓ (OPPORTUNITY)◆
The $8.5B acquisition of Arcosa is a transformative deal that will significantly expand CRH's North American aggregates and infrastructure exposure. The deal is expected to be accretive and reinforces CRH's strategy of consolidating in a fragmented market with strong secular demand
- WESCO / Data Center Growth↓ (OPPORTUNITY)◆
Data center sales surged 45% YoY to $1.5B, and backlog hit a record (+60% YoY). The company is a direct beneficiary of the AI infrastructure buildout. The current cash flow weakness is a growing pain, but the top-line trajectory is exceptional
- Willis Towers Watson / AI & Margin Expansion↓ (OPPORTUNITY)◆
The 'Propel' AI acceleration plan targeting ~30% adjusted operating margin by 2028 is a significant catalyst. Combined with a $1.5B buyback increase and strong Q2 results, WTW is showing a clear path to improved profitability and shareholder returns
- Yum China / Store Expansion & Margin Growth↓ (OPPORTUNITY)◆
Record net new store openings of 560 (+67% YoY) and the 9th consecutive quarter of OP margin expansion demonstrate strong execution. The acquisition of the Pizza Hut brand in China (closing August 2026) is a near-term catalyst for further growth
- ◆
The planned acquisition of Element Solutions, expected to close in H1 2027, is a major strategic move. Combined with strong Q2 results and raised guidance, the company is positioning itself as a diversified specialty materials leader with significant scale
- BioCardia / Insider Buying↓ (OPPORTUNITY)◆
The CEO's purchase of 5,000 shares at $0.78 is a small but positive signal from management. For a micro-cap biotech, insider buying at a low stock price can indicate a belief that the company is undervalued relative to its pipeline potential
- ChipMOS Technologies / Strong Profit Growth↓ (OPPORTUNITY)◆
Net profit surged 174% YoY in May and 187% in Q1, with EPS rising 175-200%. The company is seeing strong demand in the semiconductor space, though the trailing 4-quarter net profit margin of 3.9% suggests room for operational leverage
- ASE Technology / Revenue Acceleration↓ (OPPORTUNITY)◆
Q2 net revenues were up 36.3% YoY and 12.2% sequentially, with income before tax surging. The company is a key beneficiary of the semiconductor upcycle and advanced packaging demand, though rising raw material costs (45% of revenue) are a headwind
- Pharming Group / Narrowing Losses↓ (OPPORTUNITY)◆
Net loss improved to $3.6M from $10.3M in 1H 2025, driven by a 40% increase in Joenja revenue. The company is approaching profitability with a strong cash position ($158.3M) and a growing rare disease drug portfolio
- Virtu Financial / Market Making Strength↓ (OPPORTUNITY)◆
Market Making segment revenues surged to $1.0B from $786.6M, and Adjusted Net Trading Income rose 26.4% YoY. The company is benefiting from increased market volatility and trading volumes, a trend that could persist
Sector Themes (6)
- Data Center / AI Infrastructure Boom◆
WESCO (+45% data center sales) and AITX (largest data center order) highlight the continued strength in AI-related infrastructure spending. This is a secular theme driving growth for industrial distributors and technology providers, though it comes with working capital demands.
- Margin Compression Amidst Growth◆
A clear pattern across multiple sectors (Solstice, Magnum Ice Cream, WESCO, CRH) is that strong revenue growth is being accompanied by margin compression due to cost inflation, plant turnarounds, or higher SG&A. Investors should focus on companies that can demonstrate operating leverage, not just top-line growth.
- Broad Insider Selling at Elevated Levels◆
The coordinated insider selling at Natera and near-total exit at CoreWeave, combined with large sales at Schwab and Roivant, suggest a cautious stance from corporate insiders. This could indicate that management teams view current valuations as full or that growth headwinds are building.
- Building Materials Consolidation◆
CRH's $8.5B Arcosa acquisition is a landmark deal that signals a wave of consolidation in the North American building materials space. This theme is driven by the need for scale in aggregates and infrastructure to meet demand from reshoring and government spending.
- Mixed Performance in Consumer Staples◆
Ambev and Yum China show strong domestic performance but international weakness. Magnum Ice Cream reported growth but margin pressure. This suggests a bifurcated consumer environment where companies with strong local brands and execution are outperforming, while those with broad international exposure face headwinds.
- Cash Flow Divergence from Earnings◆
Multiple companies (CRH, WESCO, Lincoln National) reported strong earnings growth but declining operating cash flow. This divergence is a red flag for earnings quality and suggests that working capital needs or one-time items are inflating reported profits. Investors should prioritize cash flow generation.
Watch List (8)
-
The acquisition of the Pizza Hut brand in Mainland China is expected to close in August 2026. This is a key catalyst for future growth and margin expansion. Watch for closing announcement and integration details.
-
The planned acquisition is expected to close in H1 2027. Monitor for regulatory approvals and financing details. The deal could be transformative but carries integration risk.
-
The $8.5B deal is a major strategic move. Watch for shareholder vote, regulatory approvals, and any updates on financing. The deal is expected to close in late 2026 or early 2027.
-
Monitor for any further insider selling, especially if it accelerates or if executives reduce holdings significantly. The breadth of the current selling is a red flag that warrants close attention.
-
The near-total exit by the Chief Development Officer raises questions about executive retention and morale. Watch for any further executive departures or changes in the management team.
-
The sharp decline in operating cash flow is a key risk. Watch for commentary on working capital management and any signs of cash flow improvement in the coming quarters.
-
The company is targeting a $15-$17 IPO price range. Watch for the final pricing, demand from institutional investors, and the stock's performance on its Nasdaq debut under the ticker 'BRVE'.
-
The separate trading of shares, rights, and warrants begins on July 31, 2026. This could create arbitrage opportunities or price discovery for the individual components of the SPAC.
Filing Analyses
(50)
29-07-2026
Co-Chairman Bettinger Walter W sold 192,488 Common Stock at $103.90 (~$20M). 8 transactions reported in total. Bettinger Walter W holds 529,346 shares after the transaction.
- · Co-Chairman Bettinger Walter W exercised/converted 192,488 Common Stock at $52.05 (~$10M)
- · Co-Chairman Bettinger Walter W sold 192,488 Common Stock at $103.90 (~$20M)
- · Co-Chairman Bettinger Walter W exercised/converted 93,408 Common Stock at $52.05 (~$4.86M)
- · Co-Chairman Bettinger Walter W sold 42,265 Common Stock at $103.86 (~$4.39M)
- · Co-Chairman Bettinger Walter W sold 38,263 Common Stock at $105.18 (~$4.02M)
- · Co-Chairman Bettinger Walter W sold 12,880 Common Stock at $105.56 (~$1.36M)
- · Co-Chairman Bettinger Walter W exercised/converted 192,488 Nonqualified Stock Option (right to buy)
- · Co-Chairman Bettinger Walter W exercised/converted 93,408 Nonqualified Stock Option (right to buy)
29-07-2026
SVP, General Counsel Chan May K. had withheld for taxes 467 Common Stock at $62.56 (~$29.2K). Chan May K. holds 3,691 shares after the transaction.
- · SVP, General Counsel Chan May K. exercised/converted 1,448 Common Stock
- · SVP, General Counsel Chan May K. had withheld for taxes 467 Common Stock at $62.56 (~$29.2K)
- · SVP, General Counsel Chan May K. exercised/converted 1,448 Restricted Stock Units
29-07-2026
EVP, Chief Admin Officer Lo Thomas M. had withheld for taxes 934 Common Stock at $62.56 (~$58.4K). Lo Thomas M. holds 3,962 shares after the transaction.
- · EVP, Chief Admin Officer Lo Thomas M. exercised/converted 2,896 Common Stock
- · EVP, Chief Admin Officer Lo Thomas M. had withheld for taxes 934 Common Stock at $62.56 (~$58.4K)
- · EVP, Chief Admin Officer Lo Thomas M. exercised/converted 2,896 Restricted Stock Units
29-07-2026
Director Mecklenburg Gabriel M.I. was awarded 944,250 Performance-based Restricted Stock Units.
- · Director Mecklenburg Gabriel M.I. was awarded 944,250 Performance-based Restricted Stock Units
29-07-2026
CEO & Co-Founder Perez Daniel Antonio had withheld for taxes 509,423 Class B Common Stock at $74.31 (~$37.9M). 4 transactions reported in total.
- · CEO & Co-Founder Perez Daniel Antonio was awarded 944,250 Performance-based Restricted Stock Units
- · CEO & Co-Founder Perez Daniel Antonio exercised/converted 944,250 Performance-based Restricted Stock Units
- · CEO & Co-Founder Perez Daniel Antonio exercised/converted 944,250 Class B Common Stock
- · CEO & Co-Founder Perez Daniel Antonio had withheld for taxes 509,423 Class B Common Stock at $74.31 (~$37.9M)
29-07-2026
President and CEO Altman Peter bought 5,000 Common Stock at $0.78 (~$3.9K). Altman Peter holds 373,885 shares after the transaction.
- · President and CEO Altman Peter bought 5,000 Common Stock at $0.78 (~$3.9K)
29-07-2026
President & Immunovant CEO Venker Eric sold 200,000 Common Shares at $34.95 (~$6.99M). Venker Eric holds 1,613,063 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · President & Immunovant CEO Venker Eric exercised/converted 200,000 Common Shares at $3.85 (~$770K)
- · President & Immunovant CEO Venker Eric sold 200,000 Common Shares at $34.95 (~$6.99M)
- · President & Immunovant CEO Venker Eric exercised/converted 200,000 Stock Option (Right to Buy)
29-07-2026
Chief Development Officer McBee Brannin sold 5,503 Class A Common Stock at $70.35 (~$387K). 5 transactions reported in total. McBee Brannin holds 285 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Development Officer McBee Brannin sold 5,503 Class A Common Stock at $70.35 (~$387K)
- · Chief Development Officer McBee Brannin sold 5,200 Class A Common Stock at $71.07 (~$370K)
- · Chief Development Officer McBee Brannin sold 712 Class A Common Stock at $72.28 (~$51.5K)
- · Chief Development Officer McBee Brannin sold 800 Class A Common Stock at $73.30 (~$58.6K)
- · Chief Development Officer McBee Brannin sold 285 Class A Common Stock at $74.29 (~$21.2K)
29-07-2026
Chief Development Officer McBee Brannin sold 63,397 Class A Common Stock at $70.35 (~$4.46M). 25 transactions reported in total. McBee Brannin holds 912 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Development Officer McBee Brannin sold 63,397 Class A Common Stock at $70.35 (~$4.46M)
- · Chief Development Officer McBee Brannin sold 59,913 Class A Common Stock at $71.07 (~$4.26M)
- · Chief Development Officer McBee Brannin sold 8,201 Class A Common Stock at $72.28 (~$593K)
- · Chief Development Officer McBee Brannin sold 9,205 Class A Common Stock at $73.30 (~$675K)
- · Chief Development Officer McBee Brannin sold 3,284 Class A Common Stock at $74.29 (~$244K)
- · Chief Development Officer McBee Brannin sold 11,008 Class A Common Stock at $70.35 (~$774K)
- · Chief Development Officer McBee Brannin sold 10,360 Class A Common Stock at $71.06 (~$736K)
- · Chief Development Officer McBee Brannin sold 1,441 Class A Common Stock at $72.28 (~$104K)
29-07-2026
Chief Product Officer Slayter Cameron sold 3,985 Class A common stock, par value $0.001 per share at $1.67 (~$6.65K). Slayter Cameron holds 151,015 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Product Officer Slayter Cameron sold 3,985 Class A common stock, par value $0.001 per share at $1.67 (~$6.65K)
29-07-2026
COO, President Allan David Robert Malcolm exercised/converted 125,000 Class A common stock, par value $0.001 per share at $1.66 (~$208K). Allan David Robert Malcolm holds 500,000 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · COO, President Allan David Robert Malcolm exercised/converted 125,000 Class A common stock, par value $0.001 per share at $1.66 (~$208K)
- · COO, President Allan David Robert Malcolm exercised/converted 125,000 Stock Option (Nonstatutory)
29-07-2026
PRESIDENT AND COO De Cock Paul F had withheld for taxes 1,565 Common Stock at $117.14 (~$183K). De Cock Paul F holds 89,457 shares after the transaction.
- · PRESIDENT AND COO De Cock Paul F had withheld for taxes 1,565 Common Stock at $117.14 (~$183K)
29-07-2026
Director Ashiya Mona was awarded 15,435 Stock Option (Right to Buy).
- · Director Ashiya Mona was awarded 15,435 Stock Option (Right to Buy)
29-07-2026
Director Sheena Jonathan sold 288 Common Stock at $260.49 (~$75K). Sheena Jonathan holds 245,723 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Director Sheena Jonathan sold 288 Common Stock at $260.49 (~$75K)
- · Director Sheena Jonathan sold 191 Common Stock at $254.07 (~$48.5K)
29-07-2026
EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 1,718 Common Stock at $260.49 (~$448K). Rabinowitz Matthew holds 2,276,125 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · EXECUTIVE CHAIRMAN Rabinowitz Matthew sold 1,718 Common Stock at $260.49 (~$448K)
29-07-2026
SEC. AND CHIEF LEGAL OFFICER RABINOWITZ DANIEL sold 1,003 Common Stock at $254.07 (~$255K). RABINOWITZ DANIEL holds 170,407 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · SEC. AND CHIEF LEGAL OFFICER RABINOWITZ DANIEL sold 884 Common Stock at $260.49 (~$230K)
- · SEC. AND CHIEF LEGAL OFFICER RABINOWITZ DANIEL sold 1,003 Common Stock at $254.07 (~$255K)
29-07-2026
PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 1,204 Common Stock at $254.07 (~$306K). Moshkevich Solomon holds 132,429 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 1,010 Common Stock at $260.49 (~$263K)
- · PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold 1,204 Common Stock at $254.07 (~$306K)
29-07-2026
PRESIDENT, CHIEF BUS. OFFICER Fesko John sold 931 Common Stock at $254.07 (~$237K). Fesko John holds 184,069 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · PRESIDENT, CHIEF BUS. OFFICER Fesko John sold 782 Common Stock at $260.49 (~$204K)
- · PRESIDENT, CHIEF BUS. OFFICER Fesko John sold 931 Common Stock at $254.07 (~$237K)
29-07-2026
CEO AND PRESIDENT Chapman Steven Leonard sold 3,580 Common Stock at $254.07 (~$910K). Chapman Steven Leonard holds 102,973 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · CEO AND PRESIDENT Chapman Steven Leonard sold 2,190 Common Stock at $260.49 (~$570K)
- · CEO AND PRESIDENT Chapman Steven Leonard sold 3,580 Common Stock at $254.07 (~$910K)
29-07-2026
CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold 1,863 Common Stock at $249.38 (~$465K). 5 transactions reported in total. Brophy Michael Burkes holds 52,432 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold 782 Common Stock at $260.49 (~$204K)
- · CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold 1,241 Common Stock at $254.07 (~$315K)
- · CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold 1,008 Common Stock at $253.77 (~$256K)
- · CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold 170 Common Stock at $254.33 (~$43.2K)
- · CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold 1,863 Common Stock at $249.38 (~$465K)
29-07-2026
Director Zeronda Tyler was awarded 185,798 Stock Option (Right to Buy).
- · Director Zeronda Tyler was awarded 185,798 Stock Option (Right to Buy)
29-07-2026
SoftVest Advisors, LLC and related entities (collectively owning 13.3% of Permian Basin Royalty Trust) filed Amendment No. 5 to Schedule 13D on July 29, 2026, disclosing a business combination agreement entered into on July 28, 2026. Under the deal, New PBT (a SoftVest subsidiary) will acquire a majority of the Trust's assets and liabilities plus approximately 68,000 acres of surface estate and a 15% effective royalty interest from Blackbeard Holdings. Following the combination, existing unitholders will own 59.3% of New PBT common stock, while Blackbeard Security and Greybeard Energy will own 40.7%. SoftVest also entered into a voting and support agreement and a commitment and backstop agreement to backstop up to $71.16 million in unsubscribed Class A shares in a rights offering.
- · The Combination Agreement was entered into on July 28, 2026, and a preliminary proxy statement/prospectus on Form S-4 was filed the same day.
- · SoftVest agreed to vote all its eligible Units in favor of the Business Combination and against any competing proposals.
- · SoftVest and Horizon Kinetics jointly and severally committed to backstop up to $71.16 million in unsubscribed Class A shares in the Rights Offering, each covering 50%.
- · Horizon Kinetics currently beneficially owns 6,837,532 Units (not included in the Reporting Persons' ownership).
- · The Voting and Support Agreement terminates upon consummation of the transaction, termination of the Combination Agreement, or mutual written agreement.
- · The Reporting Persons disclaim membership in any group formed with Blackbeard Security or Horizon Kinetics.
29-07-2026
Southern Cross Acquisition I Sponsor Corp. and its sole shareholder Dong Chen filed a Schedule 13D disclosing beneficial ownership of 3,100,300 ordinary shares (21.1%) of Southern Cross Acquisition I Corp. as of July 22, 2026. The stake includes 2,861,000 founder shares acquired pre-IPO for $25,000 and 239,300 private placement units acquired simultaneously with the IPO. The filing states no current plans for extraordinary corporate transactions, but the Reporting Persons may acquire additional shares in the future.
- · The Sponsor transferred 5,000 founder shares to Ally Tong Zhang, 3,000 to Siu Wai Lam, and 2,000 each to three independent directors on July 16, 2026.
- · The Reporting Persons have no current plans for mergers, asset sales, board changes, delisting, or other extraordinary transactions.
- · No transactions in the ordinary shares were effected by the Reporting Persons in the past 60 days other than the transfers described.
- · The Sponsor is a Cayman Islands exempted company; Dong Chen is a citizen of the People's Republic of China.
30-07-2026
Braveheart Bio, Inc. filed Amendment No. 1 to its S-1 registration statement on July 30, 2026, for an initial public offering of 18,750,000 shares of common stock, with an estimated price range of $15.00 to $17.00 per share. The company is a clinical-stage biopharmaceutical firm focused on hypertrophic cardiomyopathy therapies, with lead candidate BHB-1893 in-licensed from Hengrui. While the offering targets up to $75 million from a cornerstone investor (Fidelity), the company has no public market for its stock, is pre-revenue, and faces significant risks including reliance on a single product candidate and clinical trial data generated by a third party.
- · The company has applied to list on Nasdaq under the symbol 'BRVE'.
- · Braveheart is an 'emerging growth company' and a 'smaller reporting company' and has elected reduced reporting requirements.
- · All clinical trials of BHB-1893 completed to date were designed, sponsored, and conducted by Hengrui, primarily in China, with one Phase 1 trial in Australia; Braveheart was not involved in their design, conduct, or oversight.
- · BHB-1893 is designed to address limitations of first-generation CMIs, including rapid onset, predictable pharmacokinetics, limited drug-drug interactions, and low LVEF cost.
- · The underwriters have a 30-day option to purchase up to an additional 2,812,500 shares.
- · The offering is contingent upon listing on Nasdaq.
30-07-2026
CRH reported net income of $1,511M for Q2 2026, up 13.4% from $1,332M in Q2 2025, and $1,331M for H1 2026, up 7.9% from $1,234M in H1 2025. Total revenues rose 5.6% to $10,777M in Q2 and 7.0% to $18,147M in H1. However, comprehensive income attributable to CRH fell 17.8% in Q2 to $1,463M and 36.8% in H1 to $1,191M, driven by a large currency translation loss of $102M in H1 versus a gain of $749M a year ago. Operating cash flow declined 28.7% to $513M in H1, while the company generated $1,676M in divestiture proceeds.
- · Americas Building Solutions revenue declined 1.9% in Q2 and 1.5% in H1, driven by a 5.8% drop in Outdoor Living Solutions to $1,551M in Q2 and a 4.9% drop to $2,748M in H1.
- · Operating cash flow fell 28.7% to $513M in H1 2026, primarily due to a $1,824M increase in accounts receivable (vs. $1,397M in H1 2025).
- · Cash and cash equivalents decreased 26.1% from $4,096M at Dec 31, 2025 to $3,025M at June 30, 2026.
- · The company generated $1,676M in proceeds from divestitures in H1 2026, compared to just $37M in H1 2025, and spent $1,110M on acquisitions (vs. $648M).
- · Long-term debt was reduced by 6.5% to $15,410M from $16,478M at year-end 2025.
- · Share repurchases totaled $607M in H1 2026, down from $644M in H1 2025; dividends paid increased to $521M from $500M.
30-07-2026
Yum China reported strong Q2 2026 results with revenue up 13% YoY to $3.1B and operating profit up 14% to $348M, marking the 9th consecutive quarter of OP margin expansion. Same-store sales grew 1% YoY (improving sequentially) with record net new store openings of 560 (up 67% YoY). However, Pizza Hut's restaurant margin declined 40 bps YoY to 12.9% due to higher delivery costs and value-for-money offerings, and KFC's restaurant margin was flat in the first half. The acquisition of the Pizza Hut brand in Mainland China is expected to close in August 2026.
- · Pizza Hut's same-store sales growth decelerated to 1% in Q2 2026 from 2% in Q2 2025.
- · Pizza Hut's restaurant margin declined 40 bps YoY to 12.9% in Q2 due to higher delivery costs, value-for-money offerings and investment in Pizza Hut Burger Bar.
- · KFC's restaurant margin in the first half of 2026 was flat year-over-year at 18.1%.
- · Delivery sales grew 26% YoY, contributing ~54% of total Company sales (up from 45%).
- · The Company targets total stores of over 20,000 by year-end 2026, with 40-50% franchise mix of net new stores.
- · Starting in 2027, the Company plans to return approximately 100% of annual free cash flow (after non-controlling interest dividends), anticipated to be ~$900M-$1B+ in 2027-2028.
- · The Pizza Hut brand acquisition in Mainland China is expected to close in August 2026, financed by an ~$1.2B offshore bridge loan.
30-07-2026
Mizuho Financial Group reported Q1 FY2026 results with total assets increasing to ¥304,283,463 million from ¥302,240,042 million at fiscal year-end 2025. Comprehensive income rose 25.8% to ¥413,801 million, while the company revised its full-year profit estimate upward by 7.6% to ¥1,400,000 million. However, the own capital ratio remained flat at 3.7%, and retained earnings declined slightly from ¥6,831,168 million to ¥6,777,359 million.
- · Cash and due from banks decreased from ¥61,567,751 million to ¥52,124,258 million.
- · Securities increased from ¥42,632,517 million to ¥49,922,242 million.
- · Loans and bills discounted increased from ¥99,753,193 million to ¥103,079,469 million.
- · Deposits slightly decreased from ¥165,937,062 million to ¥165,315,426 million.
- · Treasury stock decreased from ¥(311,529) million to ¥(51,070) million, indicating share buybacks.
- · Dividend per share estimate for fiscal 2026 is ¥150.00, up from ¥145.00 in fiscal 2025.
30-07-2026
Pharming Group N.V. reported a net loss of $3.6M for the first half of 2026, an improvement from a $10.3M loss in 1H 2025, driven by a 40% increase in Joenja revenue to $32.0M. However, total revenue declined 5.6% to $162.7M, primarily due to a 12.3% drop in RUCONEST sales to $130.7M, and operating profit swung to a loss of $3.6M from a profit of $3.8M a year earlier. The company ended the period with $158.3M in cash and cash equivalents, down from $145.3M at year-end 2025.
- · R&D expenses increased 28.9% to $57.8M in 1H 2026 from $44.8M in 1H 2025.
- · Marketing and sales expenses decreased 10.2% to $58.9M in 1H 2026 from $65.6M in 1H 2025.
- · General and administrative expenses decreased 29.8% to $30.2M in 1H 2026 from $43.0M in 1H 2025.
- · Net cash used in operating activities was $7.7M in 1H 2026 vs. $12.0M generated in 1H 2025.
- · Total assets decreased to $468.0M at June 30, 2026 from $500.0M at December 31, 2025.
- · Current liabilities decreased to $93.2M from $115.8M at year-end 2025.
- · Convertible bonds (non-current) stood at $92.4M, essentially flat vs. $92.7M at year-end 2025.
30-07-2026
Sumitomo Mitsui Trust Group, Inc. filed its quarterly 13F-HR for the period ending June 30, 2026, reporting approximately $175.06 billion in total holdings across a diversified portfolio of equities, ETFs, and ADRs. Major positions include Apple Inc. ($9.63B), Amazon.com Inc. ($5.95B), and Broadcom Inc. ($4.23B), with significant holdings also in Advanced Micro Devices ($2.84B) and Applied Materials ($1.36B). The filing reflects a broad, multi-manager strategy with holdings managed by subsidiaries including Sumitomo Mitsui Trust Bank, Amova Asset Management, and Sumitomo Mitsui Trust Asset Management.
- · The filing includes 1,080 reportable holdings with a total market value of $175,059,245,023.
- · Top holdings by value include Apple Inc. ($9.63B), Amazon.com Inc. ($5.95B), Broadcom Inc. ($4.23B), Advanced Micro Devices ($2.84B), and Applied Materials ($1.36B).
- · The filing is a combination report covering multiple managers: Sumitomo Mitsui Trust Bank, Amova Asset Management Co., Ltd., Sumitomo Mitsui Trust Asset Management Co., Ltd., Amova Asset Management UK Ltd, Amova Asset Management Asia Ltd, and AHAM Asset Management Berhad.
- · The report is signed by Hideaki Takamiya, Senior Manager of Risk Management Dept., on July 30, 2026.
30-07-2026
ASE Technology reported strong Q2 2026 results with net revenues of NT$126,148 million, up 36.3% YoY and 12.2% sequentially. Income before tax surged to NT$25,700 million from NT$18,161 million in Q1 2026, while basic EPS reached NT$4.80. However, raw material costs rose to 45% of net revenues (NT$86,253 million) from 28% in a prior period (NT$34,782 million), indicating a significant cost pressure.
- · Basic EPS for Q2 2026 was NT$4.80 (US$0.304 per ADS).
- · Diluted EPS for Q2 2026 was NT$4.61 (US$0.292 per ADS).
- · Labor cost was NT$21,920 million, representing 11% of net revenues.
- · Other net non-operating income was NT$484 million.
- · Cost of revenues increased 26.7% YoY and 10.1% sequentially.
30-07-2026
Virtu Financial reported Q2 2026 total revenues of $1,190.0 million, up 19.0% YoY, and Adjusted Net Trading Income of $717.9 million, up 26.4% YoY. However, GAAP net income declined to $284.9 million from $293.0 million in the prior-year quarter, and basic EPS slipped to $1.63 from $1.65, reflecting a mixed performance with strong top-line growth but lower profitability.
- · Board declared a quarterly cash dividend of $0.24 per share, payable September 15, 2026 to shareholders of record as of September 1, 2026.
- · Market Making segment total revenues were $1,009.2M in Q2 2026 vs $786.6M in Q2 2025; Execution Services segment total revenues were $173.5M vs $214.5M in Q2 2025 (a decline of 19.1%).
- · Execution Services segment Adjusted Net Trading Income was $138.0M in Q2 2026 vs $116.3M in Q2 2025, up 18.7%.
- · For the six months ended June 30, 2026, total revenues were $2,285.3M vs $1,837.4M in the prior year period.
- · Cash, cash equivalents and restricted cash totaled $1,133.0M; long-term debt was $2,051.1M as of June 30, 2026.
30-07-2026
Ambev reported mixed Q2 2026 results with consolidated net revenue up 6.1% YoY to R$20,148.9M and normalized EBITDA up 8.9% YoY to R$6,376.7M, driven by strong performance in Brazil (beer volume +5.0%, normalized EBITDA +12.8%). However, the CAC segment saw a volume decline of 5.4% and normalized EBITDA fell 4.9%, while Canada's volume dropped 1.8% and normalized EBITDA declined 2.9%. Net finance results improved significantly to a loss of R$486.1M from a loss of R$974.0M in 2Q25, primarily due to lower exchange losses.
- · Brazil beer volume grew 5.0% YoY to 21,034.9 thousand hl in Q2 2026, while Brazil NAB volume declined 4.4% to 7,615.3 thousand hl.
- · CAC segment volume declined 5.4% YoY to 2,659.4 thousand hl in Q2 2026, with net revenue down 7.1% and normalized EBITDA down 4.9%.
- · LAS segment volume declined 2.9% YoY to 6,015.0 thousand hl, with net revenue down 4.4% and normalized EBITDA down 2.6%.
- · Canada segment volume declined 1.8% YoY to 2,403.3 thousand hl, with net revenue down 2.1% and normalized EBITDA down 2.9%.
- · Net finance result improved to a loss of R$486.1M in Q2 2026 from a loss of R$974.0M in Q2 2025, driven by lower exchange differences (loss of R$141.2M vs R$527.5M) and lower losses on hedging instruments (R$167.2M vs R$276.3M).
- · Total assets decreased to R$138,209.0M as of June 30, 2026 from R$145,087.2M as of December 31, 2025.
- · Cash and cash equivalents decreased to R$16,610.8M from R$18,638.2M over the same period.
- · Equity attributable to Ambev's shareholders increased slightly to R$88,313.2M from R$87,914.0M.
- · The company will hold an earnings conference call on July 30, 2026 at 12:30 PM Brasília time.
30-07-2026
Magnum Ice Cream Co B.V. reported mixed H1 2026 results with total revenue growing 4.2% YoY to €4.691B and adjusted EBIT rising 7.5% to €716M. However, the overall adjusted EBITDA margin contracted 30bps to 18.7%, dragged down by a 70bps impact from Transitional Service Agreements and a 30bps impact from the India acquisition. Regional performance was uneven: Europe & ANZ delivered 4.1% organic sales growth with positive volume growth but negative price growth (-0.6%), Americas saw reported revenue decline of 1.1% with near-flat volume growth (0.1%), and AMEA reported strong 7.6% organic sales growth but with margin compression (adjusted EBITDA margin falling from 26.2% to 23.5%). Free cash flow nearly doubled to €273M from €138M.
- · H1 2026 diluted earnings per share: €0.55
- · H1 2026 adjusted earnings per share: €0.72
- · Europe & ANZ organic volume growth was 4.8% but organic price growth was -0.6% in H1 2026.
- · Americas organic volume growth was virtually flat at 0.1% in H1 2026 (Q2 2026 also 0.1%).
- · AMEA organic sales growth slowed from 10.7% in H1 2025 to 7.6% in H1 2026; organic volume growth decelerated sharply from 7.1% to 1.9%.
- · Total adjusting items increased to €129M in H1 2026 from €97M in H1 2025.
- · Depreciation and amortisation declined from €187M to €164M.
30-07-2026
ChipMOS Technologies Inc. reported strong financial results for May 2026 and Q1 2026, with revenue growing 17.7% YoY to NT$2,384 million in May and 25.4% YoY to NT$6,936 million in Q1. Net profit attributable to owners surged 174.1% YoY in May and 186.9% YoY in Q1, while EPS rose 175% and 200% respectively. However, the recent four-quarter accumulation shows a net profit margin of only 3.9%, indicating that profitability remains thin despite strong growth.
- · Trailing four-quarter (2025Q2-2026Q1) revenue was NT$25,336 million, net profit before tax NT$987 million, and profit attributable to owners NT$824 million.
- · EPS for the trailing four quarters was NT$1.17.
- · Net profit margin for the trailing four quarters was approximately 3.9% (NT$987M / NT$25,336M), indicating thin profitability despite strong growth.
30-07-2026
ING Groep N.V. filed a Form 6-K with the SEC on July 30, 2026, attaching a press release of the same date. The filing is a routine foreign issuer report for the month of July 2026, signed by Head of Media Relations Raymond Vermeulen. No financial figures or performance data are included in the filing itself, only a reference to the attached press release.
- · The filing is a Form 6-K (foreign private issuer report) for the month of July 2026.
- · The press release is dated July 30, 2026, and is attached as Exhibit 99.1.
- · The registrant's principal executive office is at Bijlmerdreef 106, 1102 CT Amsterdam, The Netherlands.
30-07-2026
Magnum Ice Cream Co B.V. reported H1 2026 revenue of €4,691M, up 4.2% year-over-year from €4,503M in H1 2025, driven by organic sales growth of 4.7% and a 2.3% contribution from acquisitions, partially offset by a 2.7% negative currency impact. Adjusted EBIT rose to €716M from €666M, with adjusted EBIT margin improving to 15.3% from 14.8%. However, the AMEA segment saw adjusted EBIT decline to €241M from €243M and adjusted EBITDA margin shrink to 23.5% from 26.2%, while the Americas segment revenue fell to €1,463M from €1,479M. The company completed two acquisitions in early 2026: a 61.9% stake in Kwality Wall’s (India) Limited and 100% of UL Ice Cream Comercial, Lda. in Portugal, for total consideration of €431M, generating €360M in goodwill.
- · Total adjusting items within operating profit were €129M in H1 2026, up from €97M in H1 2025, primarily due to acquisition and disposal-related costs of €110M and restructuring costs of €19M.
- · Net monetary loss of €13M in H1 2026 versus a net monetary gain of €27M in H1 2025, reflecting hyperinflationary market impacts.
- · Total financial liabilities increased to €3,845M at H1 2026 from €3,416M at FY 2025, driven by a rise in bonds and other loans to €3,168M from €3,077M and a jump in bank loans and overdrafts to €287M from €35M.
- · Lease liabilities increased to €226M from €143M at FY 2025.
- · The acquisitions of KWIL and ULICC contributed €96M in identifiable net assets at fair value, with goodwill of €360M representing 83.5% of total purchase consideration.
- · Non-controlling interest of €25M was recognized on the KWIL acquisition.
- · The open offer for KWIL public shares increased the Group's shareholding from 61.90% to 61.91%.
- · A refundable €16M advance payment was made for the ULICC sourcing unit pending regulatory and operational approvals.
30-07-2026
CRH reported strong Q2 2026 results with total revenues of $10.8B (+6% YoY), net income of $1.5B (+13% YoY), and Adjusted EBITDA of $2.6B (+7% YoY), driven by pricing momentum, underlying demand, and acquisitions. However, the Americas Building Solutions segment saw revenues decline 2% and Adjusted EBITDA fall 8% YoY due to divestitures, subdued residential demand, and cost inflation. The company announced a definitive $8.5B agreement to acquire Arcosa, reinforcing its North American aggregates and infrastructure position, while also completing $1.1B in acquisitions and $1.7B in divestitures during the quarter. FY26 guidance was reaffirmed.
- · Net income margin improved 90 bps YoY to 14.0%.
- · Adjusted EBITDA margin improved 30 bps YoY to 24.4%.
- · Americas Building Solutions Adjusted EBITDA margin declined 140 bps YoY to 21.8%.
- · Cement volumes in Americas Materials Solutions declined 2% YoY; cement prices declined 1% YoY.
- · Interest expense increased $20M YoY to $220M due to higher gross debt.
- · Income tax expense surged $236M YoY to $661M, mainly due to divestiture gains.
- · Net Debt increased $1.2B from Dec 31, 2025 to $15.4B.
- · CRH entered a $5.8B bridge facility to partially finance the Arcosa acquisition.
- · Share buyback program paused after completing $0.7B year-to-date; no new tranche initiated due to Arcosa deal.
- · Quarterly dividend increased 5% to $0.39 per share.
- · FY26 capital expenditure guidance lowered to $2.7B-$2.9B from $2.8B-$3.0B.
- · Arcosa acquisition expected to close in Q1 2027, subject to stockholder and regulatory approvals.
30-07-2026
Delixy Holdings Ltd announced the resignation of two independent directors, Lay Shi Wei and Yap Beng Tat Richard, effective July 29, 2026, and the appointment of two new independent directors, Zhang Chunming and Ye Changkun, effective July 30, 2026. The board committees were reconstituted accordingly. The resignations were not due to any disagreement with the company, and the board now consists of two executive and three independent directors.
- · The resignations were not the result of any disagreement with the company, its board, or management.
- · Mr. Zhang Chunming, aged 35, has nearly ten years of experience in corporate governance, risk management, compliance, and investment/financing advisory.
- · Mr. Ye Changkun, aged 42, has over ten years of professional experience in quality management, production operations, and team management.
- · The Audit Committee now comprises Wang Jinxiao (Chairman), Zhang Chunming, and Ye Changkun.
- · The Compensation Committee now comprises Zhang Chunming (Chairman), Wang Jinxiao, and Ye Changkun.
- · The Nomination Committee now comprises Wang Jinxiao (Chairman), Zhang Chunming, and Ye Changkun.
- · As a foreign private issuer, the company relies on the home country exemption under Nasdaq Listing Rule 5615(a)(3) and is not required to maintain a board comprising a majority of independent directors.
30-07-2026
WESCO International reported record second quarter 2026 net sales of $6.7 billion, up 13% YoY and 10% sequentially, driven by strong data center sales (+45% YoY to $1.5 billion) and record backlog (+60% YoY). Adjusted diluted EPS rose 35% YoY to a record $4.57, and adjusted EBITDA margin expanded 60 bps to 7.3%. However, operating cash flow declined 50% YoY to $54 million and free cash flow fell 63% to $32 million, reflecting higher working capital needs from sales growth and supplier prepayments.
- · Q2 2026 SG&A expenses rose 17.3% YoY to $1,022.7 million, driven by higher commissions, incentives, salaries, and benefits, plus $23.2 million in digital transformation costs.
- · Adjusted SG&A as a percentage of net sales increased to 15.0% in Q2 2026 from 14.6% in Q2 2025.
- · Interest expense increased $17.5 million in Q2 2026 due to higher net term debt, and a $10.0 million non-cash loss on extinguishment from redemption of 2028 Notes.
- · Gross margin improved 70 bps YoY to 21.8% in Q2 2026, driven by EES and CSS segments, partially offset by a decline in UBS segment.
- · The company raised its full-year 2026 outlook, citing favorable secular growth trends and confidence in continued execution.
- · Wesco acquired Singapore-based Newark Engineering to strengthen end-to-end capabilities and cooling solutions for data center customers.
- · Effective tax rate decreased 320 bps YoY to 22.9% in Q2 2026, largely due to higher discrete income tax benefits from stock-based awards.
- · Q2 2026 operating cash flow decline of $54.1 million was driven by a $182.8 million impact from changes in trade accounts receivable and a $155.3 million impact from other current and noncurrent assets, partially offset by a $129.9 million impact from changes in other current and noncurrent liabilities.
30-07-2026
Lincoln National Corp reported Q2 2026 net income of $1.3B ($6.72 per diluted share), up from $699M in Q2 2025, while adjusted operating income was $439M ($2.24 per share), slightly below the prior-year $427M ($2.36 per share). Life Insurance and Retirement Plan Services posted strong earnings growth, but Group Protection operating income declined 15% YoY and Annuities net outflows worsened to $2.9B from $1.2B. Holding company available liquidity net of prefunding rose to $903M, and the company completed a $500M subordinated debt issuance.
- · Holding company available liquidity (gross) was $1.803B as of June 30, 2026, up from $466M a year earlier.
- · RBC ratio remained above 420% for all quarters presented.
- · Book value per share including AOCI rose to $53.68 from $44.91 YoY.
- · Adjusted book value per share increased to $79.45 from $72.77 YoY.
- · Annuities average account balances reached a record $179B, up 12% YoY.
- · Retirement Plan Services ending account balances were a record $131B.
- · Life Insurance total margin increased 160 bps to 3.6%.
- · Group Protection total loss ratio increased 250 bps to 68.4% YoY, driven by experience refund recognition change.
- · Alternative investment income (after-tax) for Life Insurance dropped sharply to $38M in Q2 2026 from $74M in Q2 2025.
- · Consolidated alternative investment income (after-tax) fell to $41M in Q2 2026 from $80M in Q2 2025.
30-07-2026
ioneer Ltd filed a Form 6-K with the SEC for July 2026, attaching its Quarterly Report for the three months ended June 30, 2026. The filing was signed by CFO April Hashimoto. No specific financial figures or performance data are included in the cover filing itself, only the reference to the attached quarterly report.
- · The filing is a Form 6-K for the month of July 2026.
- · The attached exhibit is the Quarterly Report for the three months ended June 30, 2026.
- · The registrant's principal executive offices are at Suite 16.01, 213 Miller Street, North Sydney, NSW, 2060, Australia.
- · The registrant files annual reports under Form 20-F.
30-07-2026
British American Tobacco p.l.c. filed its Half-Year Report for the period ending June 30, 2026, via Form 6-K with the SEC on July 30, 2026. The report includes financial results for the first half of 2026, but no specific figures are provided in the filing itself. The filing also incorporates the report by reference into several existing registration statements.
- · The Half-Year Report is filed as Exhibit 1 to the Form 6-K.
- · The report is incorporated by reference into multiple Form S-8 and Form F-3 registration statements.
- · The filing is made under Commission File Number 001-38159.
30-07-2026
Ambev reported net income of R$7.36B for the six months ended June 30, 2026, up 11.6% from R$6.60B in the prior year period, driven by higher gross profit and improved operating income. Net sales were essentially flat at R$42.61B versus R$42.59B, while total comprehensive income swung to positive R$2.62B from a loss of R$1.91B, helped by lower foreign exchange translation losses. However, cash and cash equivalents declined 10.9% to R$16.61B from R$18.64B at year-end 2025, and operating cash flow improved significantly to R$7.87B from R$4.25B.
- · Gross profit for H1 2026 was R$22.03B, up 2.0% from R$21.60B in H1 2025.
- · Cost of sales decreased 2.0% to R$20.58B from R$20.99B.
- · Distribution expenses rose 0.2% to R$5.47B; commercial expenses increased 2.2% to R$4.34B; administrative expenses fell 4.2% to R$2.79B.
- · Exceptional items were a gain of R$5.6M in H1 2026 vs. a loss of R$72.6M in H1 2025.
- · Net financial results improved to a loss of R$1.54B from a loss of R$1.83B.
- · Total assets decreased 4.7% to R$138.21B from R$145.09B at year-end 2025.
- · Total equity was essentially flat at R$88.89B vs. R$88.77B.
- · Basic EPS for H1 2026 was R$0.4584, up from R$0.4100 in H1 2025.
- · Cash flow from investing activities was negative R$3.27B, driven by R$1.95B in subsidiary acquisitions and R$1.35B in capex.
- · Financing activities used R$5.67B, including R$2.65B in share buybacks and R$1.18B in dividends paid.
30-07-2026
IperionX Limited filed a Form 6-K with the SEC on July 30, 2026, attaching its Quarterly Report for the quarter ended June 30, 2026. The filing is a routine foreign issuer report and does not contain any financial figures or performance data beyond the exhibit reference.
30-07-2026
Solstice Advanced Materials reported Q2 2026 net sales of $1,148 million, up 11% YoY, driven by double-digit growth in Nuclear (+27%), Electronic Materials (+15%), Refrigerants (+13%), and Healthcare Packaging (+24%). However, Adjusted EBITDA margin contracted 218 bps to 25.3% due to plant turnaround activity and prior-year production credits, and the Refrigerants & Applied Solutions segment saw Adjusted EBITDA decline 6% YoY. The company raised full-year 2026 guidance and announced the planned acquisition of Element Solutions, expected to close in H1 2027.
- · Building Solutions & Intermediates net sales declined 1% YoY to $180M.
- · Corporate expenses increased to $54M in Q2 2026 from $46M in Q2 2025 due to incremental standalone public company costs.
- · Income tax expense decreased to $42M in Q2 2026 from $101M in Q2 2025; effective tax rate dropped to 24% from 51%.
- · The company raised full-year 2026 net sales guidance to $4,125M-$4,185M (from $3,900M-$4,100M) and Adjusted EBITDA guidance to $1,035M-$1,055M (from $975M-$1,025M).
- · Q3 2026 net sales guidance is $990M-$1,030M.
- · Capital expenditures guidance for full-year 2026 raised to $420M-$440M (from $400M-$425M).
- · The company expects RAS segment to generate mid-30% Adjusted EBITDA margins in H2 2026.
- · Quarterly dividend of $0.075 per share declared, payable September 10, 2026.
- · The acquisition of Element Solutions is a cash-and-stock transaction subject to shareholder and regulatory approvals, expected to close in H1 2027.
30-07-2026
Quince Therapeutics, Inc. filed Amendment No. 2 to its Form 8-K to include audited financial statements of Orphai Therapeutics for the years ended December 31, 2025 and 2024, and unaudited interim financials for Q1 2026 and 2025, along with pro forma combined financial information. The filing also incorporates business and risk factor information of Orphai following the acquisition completed on May 17, 2026. No specific financial performance figures are disclosed in this amendment, so no period-over-period comparisons are available.
- · The acquisition of Orphai was completed on May 17, 2026.
- · Audited financial statements of Orphai are provided for years ended December 31, 2025 and 2024.
- · Unaudited interim condensed consolidated financial statements of Orphai are provided for the three months ended March 31, 2026 and 2025.
- · Unaudited pro forma condensed combined financial information of the Company is provided for the three months ended March 31, 2026 and the year ended December 31, 2025.
- · Retention bonus agreements were entered into with Dirk Thye and Brendan Hannah on May 17, 2026.
- · Employment letters with Brigette Roberts were effective May 18, 2026 (Company) and May 12, 2026 (Orphai).
30-07-2026
WTW reported Q2 2026 revenue of $2.47B, up 9% YoY (organic growth 5%), but net income fell 30% to $231M and diluted EPS dropped 27% to $2.43. Adjusted diluted EPS rose 17% to $3.35, and adjusted operating margin improved 100 bps to 19.5%. The company announced Propel, an AI acceleration plan targeting ~30% adjusted operating margin by 2028, and increased its share repurchase authority by $1.5B.
- · Career revenue within HWC was flat on an organic basis, constrained by the Middle East conflict.
- · Willis Re joint venture expected to be a ~$0.30 headwind on Adjusted Diluted EPS in 2026.
- · Newfront acquisition expected to be ~$0.10 dilutive to Adjusted EPS in 2026.
- · Foreign exchange expected to provide a ~$0.35 tailwind on Adjusted Diluted EPS for full-year 2026.
- · Company expects share repurchases of $1.0B or greater in 2026.
- · Propel plan targets ~$400M in run-rate savings with a cash-cost-to-achieve ratio of ~1.6x.
- · HWC segment operating margin improved only 30 bps to 24.1%.
- · R&B segment operating margin improved 100 bps to 22.2%.
30-07-2026
NanoViricides, Inc. announced a registered direct offering of approximately $3.8 million with a single institutional investor, issuing 2,516,339 shares of common stock (or pre-funded warrants) and accompanying warrants exercisable at $1.75 per share for five and a half years. The offering is expected to close on July 27, 2026, with D. Boral Capital LLC acting as placement agent. The company is a clinical-stage antiviral developer with its lead drug NV-387 having Orphan Drug Designation, but the offering dilutes existing shareholders and the company remains pre-revenue.
- · Each whole warrant has an exercise price of $1.75 per share and expires five and a half years from issuance.
- · The offering is conducted under an effective shelf registration statement on Form S-3 (Registration No. 333-296790), declared effective by the SEC on June 15, 2026.
- · NV-387 has Orphan Drug Designation from the FDA, potentially providing 7 years market exclusivity, tax credits, and fee exemptions upon approval.
- · NV-387 was found effective in lethal animal infection models of Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.
30-07-2026
AITX announced via an 8-K filing on July 30, 2026, that its subsidiary RAD received its largest data center construction order to date. The filing includes a press release as an exhibit, but no financial terms or comparative performance data are disclosed.
- · The order is described as the largest data center construction order to date for RAD, AITX's subsidiary.
- · No specific dollar value, volume, or timeline for the order was disclosed in the filing.
- · The press release is attached as Exhibit 99.1 but its full content is not included in the 8-K text.
30-07-2026
Futurewave Acquisition Corporation announced that holders of its units may elect to separately trade the ordinary shares, rights, and warrants included in the units, commencing on or about July 31, 2026. The units not separated will continue to trade on the Nasdaq Capital Market under the symbol "FWACU," while the separated securities will trade under "FWAC," "FWACR," and "FWACW." This is a procedural update regarding the separability of the company's unit structure and does not involve any financial results or material changes in operations.
- · The separate trading of ordinary shares, rights, and warrants will commence on or about July 31, 2026.
- · Holders must contact their brokers to have Continental Stock Transfer & Trust Company separate the units.
- · The press release announcing the separate trading was issued on July 29, 2026, and is attached as Exhibit 99.1.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 50 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Pre-Market SEC Filings Roundup
🇺🇸 More from United States
View all →July 23, 2026
USA Corporate Events Calendar — July 23, 2026
USA Corporate Events Calendar
July 23, 2026
USA Earnings Calls Schedule — July 23, 2026
USA Earnings Calls Schedule
July 22, 2026
S&P 500 Financials Sector SEC Filings — July 22, 2026
S&P 500 Financials Sector SEC Filings
July 22, 2026
Nasdaq 100 Stocks SEC Filings — July 22, 2026
Nasdaq 100 Stocks SEC Filings